Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Stacy Ku
TD

Stacy Ku

TD Cowen
Wall Street Analyst
★★★☆☆
#1656
on 13Foresight · ranked by our own returns
28%
Success Rate
-11.6%
Average Return
10 of 36 calls profitable · +22.2% vs benchmark
S&P 500 (SPY)
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 28% of Stacy Ku's ratings turned a profit when each position was held for 1 year — averaging -11.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

76 Buy 0 Hold 0 Sell
Stacy's Stock Coverage 15 ratings · 2026-11-10
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
LENZ
LENZ Therapeutics
 Oct 29, 2026 BUY Buy
+470.0% avg upside
17 analysts
$45.00
1375.41% Upside
 +22.9% ·
GB:0NZT
UCB SA
 Oct 23, 2026 BUY Buy
-19.4% avg upside
19 analysts
$340.00
21.35% Upside
 +0.0% ·
VRCA
Verrica Pharmaceuticals
 Oct 21, 2026 BUY Strong Buy
+411.2% avg upside
9 analysts
$20.00
497.04% Upside
 -5.8% ·
BCRX
BioCryst
 Oct 21, 2026 BUY Strong Buy
+113.8% avg upside
24 analysts
$30.00
254.12% Upside
 -1.6% ·
TNXP
Tonix Pharma
 Oct 21, 2026 BUY Strong Buy
+415.4% avg upside
9 analysts
$22.00
331.33% Upside
 -13.3% ·
SUPN
Supernus Pharmaceuticals
 Oct 21, 2026 BUY Strong Buy
+30.3% avg upside
9 analysts
$65.00
55.06% Upside
 -3.1% ·
AUPH
Aurinia Pharmaceuticals
 Aug 19, 2026 BUY Strong Buy
-4.6% avg upside
12 analysts
$17.00
2.07% Upside
 +1.8% ·
UCBJY
UCB SA
 Jul 30, 2026 BUY Strong Buy
-3.1% avg upside
2 analysts
$165.00
5.30% Upside
 +24.9% ·
YARW
Yarrow Bioscience
 Jul 27, 2026 BUY Strong Buy
+38.5% avg upside
9 analysts
 — -45.4% ·
AVTX
Avalo Therapeutics
 Jun 11, 2026 BUY Strong Buy
+561.5% avg upside
20 analysts
 — -49.3% ·
SLGL
Sol-Gel Technologies
 May 29, 2026 BUY Strong Buy
+15.1% avg upside
6 analysts
 — -13.6% ·
TARA
Protara Therapeutics
 May 20, 2026 BUY Strong Buy
+1907.3% avg upside
21 analysts
$30.00
1109.64% Upside
 -47.3% ·
GRCE
Grace Therapeutics
 Apr 23, 2026 BUY Strong Buy
+210.4% avg upside
9 analysts
$8.00
312.47% Upside
 -21.3% ·
DMAC
Diamedica Therapeutics
 Oct 30, 2025 BUY Strong Buy
+65.9% avg upside
12 analysts
 — +32.1% ·
MLTX
MoonLake Immunotherapeutics
 Feb 26, 2025 BUY Buy
+158.9% avg upside
20 analysts
 — -58.3% ·
🔒 10 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Stacy Ku — Frequently Asked Questions
How accurate are Stacy Ku's stock ratings?
Based on the calls 13Foresight could measure, about 28% of Stacy's ratings were profitable over a one-year hold, with an average return of -11.6% per rating, or +22.2% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Stacy ranked on 13Foresight?
Stacy Ku is currently ranked #1656 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Stacy cover?
Stacy most recently has ratings on LENZ, GB:0NZT, VRCA, BCRX, TNXP, SUPN, AUPH, UCBJY, YARW, AVTX, SLGL, TARA and 3 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.